Source: Annual Congress 2005 - Various aspects of pulmonary fibrosis
Disease area: Interstitial lung diseases



Rating:

Share or cite this content

Citations should be made in the following way:
J. S. Loutit, S. Safrin, S. Suzuki, W. Z. Bradford (Brisbane, United States Of America). Serious adverse events (SAEs) of the respiratory tract in patients with idiopathic pulmonary fibrosis (IPF) treated with interferon gamma-1b (IFN-γ 1b) in three trials. Eur Respir J 2005; 26: Suppl. 49, 2201

Member's Comments

No comment yet.

Related content which might interest you: Patterns of discontinuation in the long-term RECAP study of pirfenidone (PFD) in patients with idiopathic pulmonary fibrosis (IPF) Source: International Congress 2017 – Idiopathic pulmonary fibrosis (IPF): treatment highlights Year: 2017 Safety and tolerability of pirfenidone (PFD) in patients with idiopathic pulmonary fibrosis (IPF) receiving commonly used concomitant medications Source: Annual Congress 2012 - Diffuse parenchymal lung disease: clinical profiles and collagen vascular disease Year: 2012 The long-term safety of pirfenidone (PFD) in patients with idiopathic pulmonary fibrosis (IPF) Source: Annual Congress 2012 - Idiopathic pulmonary fibrosis Year: 2012 Effect of pirfenidone on treatment-emergent (TE) all-cause mortality (ACM) in patients with idiopathic pulmonary fibrosis (IPF): Pooled data analysis from ASCEND and CAPACITY Source: International Congress 2015 – New frontiers in the management of interstitial and orphan lung diseases Year: 2015 Impact of bisphosphonate (BP) use on lung function decline and treatment response in patients (pts) with idiopathic pulmonary fibrosis (IPF) Source: Virtual Congress 2020 – News on diagnosis and therapy of idiopathic pulmonary fibrosis Year: 2020 Efficacy and safety of etanercept in patients with idiopathic pulmonary fibrosis (IPF) Source: Eur Respir J 2006; 28: Suppl. 50, 767s Year: 2006 Incidence of multiple progression events in patients with idiopathic pulmonary fibrosis (IPF) in the pooled CAPACITY and ASCEND trials Source: International Congress 2017 – Idiopathic pulmonary fibrosis (IPF): treatment highlights Year: 2017 Respiratory infections in patients with idiopathic pulmonary fibrosis (IPF) Source: Annual Congress 2009 - Idiopathic pulmonary fibrosis: concepts and mechanisms Year: 2009 Vulnerability of fatal infection under steroid treatment in patients with idiopathic pulmonary fibrosis (IPF) Source: Eur Respir J 2002; 20: Suppl. 38, 354s Year: 2002 Are there differences in response to pulmonary rehabilitation (PR) in idiopathic pulmonary fibrosis (IPF) and COPD patients? Source: International Congress 2017 – New insights into pulmonary rehabilitation in patients with chronic lung diseases Year: 2017 Long-term safety of pirfenidone (PFD) in patients with idiopathic pulmonary fibrosis (IPF): Pooled analysis of 4 clinical trials Source: International Congress 2016 – IPF treatment I Year: 2016 Differential therapy of acute respiratory failure (ARF) in chronic obstructive pulmonary disease (COPD) patients with predominance of emphysema (PE) and predominance of bronchitis (PB) Source: Eur Respir J 2006; 28: Suppl. 50, 395s Year: 2006 Fatigue in patients with idiopathic pulmonary fibrosis (IPF) from the pooled pirfenidone (PFD) Phase III trials Source: International Congress 2017 – Idiopathic pulmonary fibrosis: from the bench to the bedside Year: 2017 Phase 2B dose selection of BG00011 for the treatment of idiopathic pulmonary fibrosis (IPF) Source: International Congress 2018 – Regenerative and anti-fibrotic approaches Year: 2018 Effect of metformin on clinically relevant outcomes in patients with idiopathic pulmonary fibrosis (IPF) Source: International Congress 2017 – ILDs: clinical aspects Year: 2017 Efficacy and tolerability of budesonide/formoterol (B/F) added to tiotropium (T) vs T alone in East-Asian patients (pts) with severe/very severe chronic obstructive pulmonary disease (COPD) Source: International Congress 2014 – Clinical trials of drugs and biomarkers for respiratory diseases Year: 2014 Surfactant protein D (SPD) like marker of effectiveness in patients (pts) with acute exacerbations (AE) of COPD ofphosphatidylcholine treatment outcomes Source: International Congress 2015 – Different data in COPD Year: 2015 Bosentan in idiopathic pulmonary fibrosis (IPF): quality of life (QOL) results of the BUILD 1 study Source: Annual Congress 2006 - Quality of life in various respiratory diseases Year: 2006 Almost half the patients treated for pulmonary tuberculosis (TB) show evidence of obstructive airways disease (OAD) Source: Annual Congress 2007 - Epidemiological and clinical aspects of tuberculosis control Year: 2007 Benefit of continued pirfenidone treatment following hospitalisation within the first 6 months of therapy—Ad hoc analysis from three phase 3 trials in patients with idiopathic pulmonary fibrosis (IPF) Source: International Congress 2015 – New frontiers in the management of interstitial and orphan lung diseases Year: 2015